Current news and events

Collaboration on artificial intelligence:Improving lung and breast cancer care through AI-driven precision diagnostics

Åslaug Helland, OUH participant
Åslaug Helland, OUH participant

Oslo University Hospital  and Karolinska Institutet (KI) have entered a postdoctoral partnership with AstraZeneca. The aim is to improve lung and breast cancer care through AI-driven precision diagnostics.

In Oslo, we are welcoming Anna Christina Garvert as a postdoc in lung cancer, and Francisco Peña has been selected and started at KI working on breast cancer. They will be developing AI-based tools for precision medicine in cancer, utilizing existing diagnostic and clinical data to enhance patient outcomes.



Research awards to the Department of Gastroenterology 

During the annual meeting of the Norwegian Gastroenterology Association held in Lillehammer from February 8th to 11th, the Department of Gastroenterology received four research awards. Senior consultant and researcher Håvard Midgard, and physician and PhD fellow Charlotte Bache-Wiig Mathisen, received best abstract rewards for their works "Sustained virologic response and reinfection following HCV treatment among hospitalized people who inject drugs: Follow-up data from the OPPORTUNI-C trial" and "A novel diagnostic serum protein signature for pediatric inflammatory bowel disease." 

Nature Communications article from Raiborg project group:Cancer cells transfer their invasive properties to non-invasive cells

Eva WenzelFirst author
Eva Wenzel
First author

Cancer cells degrade and invade their surrounding tissue by use of the enzyme MT1-MMP, which is expressed on their cell surface. In a new article published in Nature Communications on February 10, 2024, Eva Wenzel and her co-workers in Camilla Raiborg’s project group identify a new mechanism for cancer cell invasion, namely that cancer cells can transfer their invasive properties to non-invasive cells. They show how invasive cancer cells secrete catalytically active soluble forms of MT1-MMP, which dock on the surface of other cells. This enables non-invasive recipient cells to degrade and invade into the extracellular matrix, by use of the newly acquired MT1-MMP enzyme. 

Publication in Science:Treatment-induced resistance mutations in BTK can be overcome by a clinical-stage BTK degrader

Sigrid S. Skånland
Sigrid S. Skånland

Sigrid S. Skånland, project group leader at Department of Cancer Immunology, did a research stay at Memorial Sloan Kettering Cancer Center in New York in 2022. The work she did while she was in the group of Dr. Omar Abdel-Wahab has now been published in Science.

Bruton’s tyrosine kinase (BTK) inhibitors are used to treat the B-cell malignancy chronic lymphocytic leukemia (CLL). Resistance mutations to the first generation of inhibitors are well characterized and have formed the rationale for a new generation of inhibitors. However, also these lead to alterations in BTK over time.

Application deadline - May 15th 2024New call from National program for clinical therapy research in the specialist health service

A new call has been made for research funds from the National Program for Clinical Treatment Research in the Specialist Health Service (KLINBEFORSK). The regional health organizations announce about NOK 170 million for national clinical treatment studies in 2024.

In this year's call, priority will be given to applications for clinical treatment research within proton therapy.

Application deadline - May 15th 2024 4.00 PM



Covered by Dagens Medisin:Calling for even more participants for the record-breaking Norwegian Atrial Fibrillation Self-screening Trial (NORSCREEN)

Sigrun HalvorsenProject leader
Sigrun Halvorsen
Project leader
The Norwegian study NORSCREEN  is funded by the regional health authorities through the KLINBEFORSK programme,and will study whether self-screening for atrial fibrillation (AF) with continuous ECG for 3-7 days in individuals 65 years or older with increased risk for stroke, and initiation of therapy in those with detected AF, will reduce the incidence of stroke and improve long-term outcome.
The study is chaired from Oslo University Hospital Ullevål by project leader professor Sigrun Halvorsen at the Department of Cardiology, Ullevål. The study will include patients from all Norway, and represents a collaboration between all the four health regions. 


Announcement: nominate a scientist for the 2024 OUH research awardsExcellent Researcher Award and Early Career Award

2023 award winners. From left: Kushtrim Kryeziu, Bente Halvorsen and Håvard Ole Skjerven
2023 award winners. From left: Kushtrim Kryeziu, Bente Halvorsen and Håvard Ole Skjerven

Oslo University Hospital hereby announce research awards in the following two catagories for 2024:

  • Excellent Researcher Award (one prize, 400.000 NOK)
  • Early Career Award (two prizes of 200.000 NOK each)

Closing date for nominations: March 6th 2024.


Research Funding for Translational Epilepsy Research

Kjell Heuser
Kjell Heuser

The epilepsy research community at the Department of Neurology, Oslo University Hospital, has recently received research funding totaling approximately 8 million Norwegian kroner for translational epilepsy research. This includes a grant of about 6.6 million kroner from the South-Eastern Norway Regional Health Authority and a grant of about 1.4 million kroner from the Lundbeck Foundation.

The funds will be utilized in translational epilepsy research led by Senior Neurologist Kjell Heuser, in collaboration with the Letten Centre at the Institute of Basic Medical Sciences at the University of Oslo, led by Rune Enger. The project supported by Lundbeck involves collaboration with Prof. Christoph Beier at Odense University Hospital.

Mother collecting money for supporting precision warfare against cancer cells led by Johanna Olweus

Johanna Olweus
Johanna Olweus

20-year-old Victor Dyreng asked his mother to raise money for cancer research before he died of acute lymphoblastic leukemia (ALL) in February 2023. The mother is now collecting money for the research of Professor Johanna Olweus at the Department for Cancer Immunology at Oslo University Hospital.
Olweus is working on a new type of immunotherapy where immune cells are equipped with "heat-seeking missiles" to find and kill cancer cells. The researchers hope to start testing the treatment on humans during 2025.
The story is covered in a feature article in national newspaper VG.

More news from the archive